Trump administration plans to take tobacco regulation out of FDA hands

The US Food and Drug Administration (FDA) is to lose its power to regulate tobacco and e-cigarette products if Congress passes president Donald Trump’s proposed budget for fiscal year 2021.

The Trump administration’s budget request to Congress proposes that the FDA’s Center for Tobacco Products (CTP) be spun off to form a new agency focused on tobacco enforcement within the Department of Health and Human Services.

“This new agency would be led by a Senate-confirmed Director in order to increase direct accountability and more effectively respond to this critical area of public health concern,” the budget states. “A new agency with the singular mission on tobacco and its impact on public health would have greater capacity to respond strategically to the growing complexity of new tobacco products.”

Critics, including some industry groups, are concerned that this proposal will drastically change the regulatory structure for tobacco and other drugs. The CTP currently operates on a budget largely generated by user fees and a variety of smaller appropriations from the federal general fund.

At the same time the Bureau of Alcohol, Tobacco, and Firearms (ATF) would lose its enforcement responsibilities to the Alcohol and Tobacco Tax and Trade Bureau (TTB) in the Department of the Treasury.

 

PMTA process thrown into question

 

“This transfer would enable the ATF to hone its focus on activities that protect U.S. communities from violent criminals and criminal organizations while consolidating duplicative alcohol and tobacco enforcement mechanisms within the TTB,” the budget states. “By allowing ATF to focus exclusively on its firearms and explosives mandates, this transfer would enable Treasury and DOJ [Department of Justice] to more efficiently and effectively protect the nation.”

The FDA changes are the most noteworthy. When the Obama administration successfully lobbied Congress for the passage of the landmark Tobacco Control Act of 2009, the FDA was granted the central authority to regulate tobacco products across the entire executive branch.

This mandate includes the premarket tobacco products application (PMTA) regulatory pathway and to ensure smoke nicotine products follow similar regulatory guidelines.

The intention of this regulatory structure is to empower compliance from companies who pay to seek product and scientific approval for new and existing products. E-cigarette makers and e-liquid producers, especially, are implored to file PMTA applications with the FDA so that these companies can return the products to the market while in compliance. The introduction of new legislation would be required to shift the authority of the Tobacco Control Act to the new tobacco-focused agency.

Changing this structure could put at risk the jobs of hundreds of employees working to regulate the tobacco industry, Charles Gardner of the Foundation for a Smoke-Free World told TobaccoIntelligence.

“That’s 1000 FDA jobs and $713m in funding from Big Tobacco this year,” said Gardner, director of the foundation’s health science and technology program. “Thanks to FDA’s 8th August 2016 deeming regulations, FDA’s role has been to freeze product innovation, preventing manufacturers from making their own safety improvements.”

 

‘Only Big Tobacco companies left’

 

Other fears overshadowing the proposal include the coming PMTA deadline of 12th May 2020, which requires e-cigarette firms to submit product applications or face indefinite closure.

Subscribe to our newsletter

Join in to hear about news, events, and podcasts in the sector

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.

“The PMTA deadline, if enforced, will cause a massive consolidation of the vaping industry that leaves only a few big companies in business. Most of those will be Big Tobacco companies,” Gardner noted, adding that any potential agency reorganisation could further complicate these processes.

Conversely, Gregory Conley, president of the American Vaping Association, was optimistic.

“This proposal by the Trump administration could be a signal that HHS [health and human services] secretary Alex Azar is serious about streamlining the regulatory process for vaping products to keep thousands of small businesses from going under in the coming months,” Conley said. “Accomplishing this will require a lot of hard work and dedication, so it would be helpful to have someone new whose sole job is to focus on tobacco and nicotine regulation.”

Lindsey Stroud, a tobacco harm reduction expert and the state government affairs manager for the conservative Heartland Institute, took a similar view.

“I would applaud any move that gets the FDA out of the business of regulating tobacco products,” Stroud said. “If freed from regulating tobacco products, the FDA could work on fast-tracking prescription medications and getting life-saving drugs to the marketplace.”

 

‘A recipe for further delay’

 

There is still a degree of uncertainty over the creation of a new tobacco regulatory framework. Michelle Minton, a senior fellow at the pro-industry Competitive Enterprise Institute, believes this proposal is not ideal for the current policy and political environment.

“We don’t need another agency focused on ‘tobacco’,” Minton said. “What we need is an agency any agency to recognise that some forms are of lower risk than others and should be regulated as such.

“Since all agencies are prone to expansion and mission creep, this portends bad things, not just for lower-risk alternatives to combustible tobacco, but for any other ‘irredeemable’ substances, like recreational cannabis.”

Tobacco control groups and public health advocacy NGOs collectively oppose this budget proposal, too, but for different reasons.

Matthew Myers, president of the Campaign for Tobacco-Free Kids, called Trump’s proposal to shift regulatory enforcement a “recipe for further delay in protecting kids from e-cigarettes”.

“The administration should be taking strong and immediate action to protect kids, including banning all flavored e-cigarettes and enforcing the May 12 deadline for e-cigarette makers to apply to the FDA to keep their products on the market,” Myers said, adding that the “proposal is yet another giveaway to the tobacco and e-cigarette industry from an administration that recently sided with the industry over kids by leaving thousands of flavored e-cigarettes on the market.”

 

What This Means: While it gives rise to an inevitable mix of hope and suspicion, the full and precise reasoning behind the Trump administration’s proposal to take tobacco and e-cigarette regulation out of the FDA’s hands is not entirely clear other than being another instance of overturning an Obama era plan.

What is also unclear is how the proposed new agency would be funded, and how it would compare with the current CTP in terms of budget and size. Would it just be the existing CTP transferred out of the FDA, on a similar scale and with similar funding, or would it be a complete rethink in terms of how it is operated, staffed, and paid for?

Michael McGrady TobaccoIntelligence US correspondent

Author default picture

TobaccoIntelligence

This article was written by one of TobaccoIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual nicotine markets.

Our Key Benefits

The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation